SCHEMBL801670

SCHEMBL801670

Cc1ccccc1-c1nc(Nc2n[nH]c3ccccc23)nc(N2CCSCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 9/20 0.43
CYP1A2 P05177 6/20 0.38
CYP3A4 P08684 6/20 0.38
CYP2D6 P10635 5/20 0.38
CLK4 Q9HAZ1 4/20 0.38
TSHR P16473 3/20 0.38
ADRA2A P08913 2/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CB P42338 1/20 0.36
MTOR P42345 1/20 0.36
PIK3CG P48736 1/20 0.36
HSD17B10 Q99714 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TRPA1 O75762 1/20 0.36
USP2 O75604 3/20 0.35
ALOX15 P16050 3/20 0.35
CYP2C19 P33261 3/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK1 P28482 1/20 0.35
CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802094 0.90 PIK3CA (0.45) PIK3CACYP1A2CYP3A4CYP2D6CLK4
SCHEMBL802694 0.89 CYP1A2 (0.50) PIK3CACYP1A2CYP3A4CYP2D6CLK4
SCHEMBL12619918 0.86 PIK3CA (0.42) PIK3CACYP1A2CYP3A4CYP2D6CLK4
SCHEMBL801704 0.84 PIK3CA (0.40) PIK3CACYP1A2CYP3A4CYP2D6CLK4
SCHEMBL801672 0.78 ABCB1 (0.46) PIK3CACYP1A2CYP3A4CYP2D6HSD17B10
SCHEMBL805614 0.77 PIK3CA (0.43) PIK3CACYP1A2CYP3A4CYP2D6CLK4
SCHEMBL13055210 0.77 PIK3CA (0.35) PIK3CA
SCHEMBL12619932 0.77 CYP1A2 (0.53) PIK3CACYP1A2CYP3A4CYP2D6CLK4
SCHEMBL801723 0.76 PDE5A (0.40) CYP1A2CYP3A4CYP2D6CLK4TSHR
SCHEMBL802311 0.76 RAB9A (0.46) CYP1A2CYP3A4CYP2D6CLK4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 PIK3CA 246/4885CYP1A2 3042/4885CYP3A4 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.